DF
MCID: DNG005
MIFTS: 55

Dengue Virus (DF)

Categories: Genetic diseases, Infectious diseases, Liver diseases, Rare diseases

Aliases & Classifications for Dengue Virus

MalaCards integrated aliases for Dengue Virus:

Name: Dengue Virus 57
Dengue Fever, Protection Against 57 13 6
Dengue Virus, Susceptibility to 57 29
Dengue Fever 58 70
Virus, Dengue, Susceptibility to 39
Dengue Virus Infection 58
Df 58

Characteristics:

Orphanet epidemiological data:

58
dengue fever
Prevalence: >1/1000 (Worldwide),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

OMIM® 57 614371
MESH via Orphanet 45 D003715
ICD10 via Orphanet 33 A97.0 A97.1 A97.2 more
UMLS via Orphanet 71 C0011311 C0019100 C0376300
Orphanet 58 ORPHA99828
UMLS 70 C0011311

Summaries for Dengue Virus

OMIM® : 57 Dengue virus is a flavivirus belonging to the family Flaviviridae. Its principal vector is Aedes aegypti, a highly urbanized, daytime-biting mosquito that breeds in stored water. There are 4 antigenetically variant serotypes of dengue virus, DEN-1 to DEN-4, and type-specific immunity against one serotype cannot block infection with another serotype. Disease manifestations following dengue infection range from subclinical infection to severe and fatal disease, with age, gender, genotype, immunologic status, and flavivirus infection history of the host all influencing disease severity. Primary infection is mainly associated with dengue fever (DF). Symptoms of DF typically appear 4 to 7 days after the mosquito bite and include high fever, headache, retroocular pain, conjunctival changes, and facial flushing. Although primary dengue infections are mostly recovered, a secondary infection with a different serotype of the virus leads to the complex condition of dengue hemorrhagic fever (DHF) with plasma leakage and thrombocytopenia or a more fatal condition, dengue shock syndrome (DSS). High fever, hemorrhagic phenomenon, hepatomegaly, and circulatory failure are mainly associated with DHF. Hemorrhages in DHF are seen in skin, subcutaneous tissues, heart, liver, and gastrointestinal tract. An estimated 50 to 100 million illnesses due to dengue infection occur annually, including 250,000 to 500,000 cases of DHF and 24,000 deaths. About 2.5 billion people are estimated to be at risk, particularly those living in tropical and subtropical areas of Asia and Latin America (reviews by Faheem et al. (2011), Whitehorn and Simmons (2011), and Guzman et al. (2010)). (614371) (Updated 05-Apr-2021)

MalaCards based summary : Dengue Virus, also known as dengue fever, protection against, is related to dengue shock syndrome and west nile virus, and has symptoms including fever and pruritus. An important gene associated with Dengue Virus is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include endothelial, t cells and monocytes, and related phenotypes are nausea and vomiting and hypotension

Wikipedia : 73 Dengue virus (DENV) is the cause of dengue fever. It is a mosquito-borne, single positive-stranded RNA... more...

Related Diseases for Dengue Virus

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 436)
# Related Disease Score Top Affiliating Genes
1 dengue shock syndrome 32.6 STAT2 CLEC5A CD209
2 west nile virus 31.6 RSAD2 IFITM3 IFITM2 IFITM1 IFIH1 DDX58
3 japanese encephalitis 31.4 STAT2 RSAD2 DDX58 CD209
4 encephalitis 31.4 RSAD2 RPSA DDX58 CD209
5 chikungunya 31.4 RSAD2 OAS3 DDX58 CD209
6 viral infectious disease 31.1 STAT2 IFIH1 DDX58 CD209
7 zika fever 31.1 STAT2 DDX58 CD209
8 severe acute respiratory syndrome 30.8 IFIH1 DDX58 CD209
9 tick-borne encephalitis 30.7 RSAD2 OAS3 DDX58 CD209
10 rift valley fever 30.5 IFITM3 IFITM2 IFITM1 CD209
11 measles 30.5 STAT2 IFIH1 DDX58 CD209
12 west nile fever 30.4 OAS3 CD209
13 hepatitis c virus 30.4 RSAD2 IFITM1 IFIH1 DDX58
14 herpes simplex 30.4 STAT2 IFIH1 DDX58 CD209
15 stomatitis 30.3 RSAD2 IFITM3 IFITM2 DDX58
16 hepatitis 30.3 RSAD2 IFIH1 HAVCR1 DDX58
17 lassa fever 30.1 IFIH1 DDX58 CD209
18 herpangina 30.1 STAT2 IFIH1 DDX58
19 influenza 30.0 RSAD2 PAF1 IFITM3 IFITM2 IFITM1 IFIH1
20 dengue disease 11.8
21 dengue hemorrhagic fever 11.5
22 asymptomatic dengue 11.3
23 yellow fever 10.9
24 thrombocytopenia 10.8
25 exanthem 10.6
26 cytokine deficiency 10.6
27 disease by infectious agent 10.6
28 vaccinia 10.5
29 severe combined immunodeficiency 10.5
30 microcephaly 10.4
31 neutropenia 10.4
32 guillain-barre syndrome 10.4
33 hemorrhagic disease 10.4
34 appendicitis 10.3
35 st. louis encephalitis 10.3
36 helix syndrome 10.3
37 myelitis 10.3
38 48,xyyy 10.3
39 viral hemorrhagic fever 10.3
40 acute pancreatitis 10.3
41 myositis 10.3
42 malaria 10.3
43 acute liver failure 10.3
44 singleton-merten syndrome 10.3 IFIH1 DDX58
45 coronavirus infectious disease 10.2 IFIH1 DDX58 CD209
46 hepatitis c 10.2
47 viral encephalitis 10.2
48 viral hepatitis 10.2
49 scotoma 10.2
50 croup 10.2 IFIH1 DDX58

Graphical network of the top 20 diseases related to Dengue Virus:



Diseases related to Dengue Virus

Symptoms & Phenotypes for Dengue Virus

Human phenotypes related to Dengue Virus:

58 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 58 Occasional (29-5%)
2 hypotension 58 Occasional (29-5%)
3 hepatomegaly 58 Occasional (29-5%)
4 fever 58 Very frequent (99-80%)
5 ascites 58 Occasional (29-5%)
6 thrombocytopenia 58 Occasional (29-5%)
7 abdominal pain 58 Frequent (79-30%)
8 arthralgia 58 Frequent (79-30%)
9 gastrointestinal hemorrhage 58 Occasional (29-5%)
10 epistaxis 58 Occasional (29-5%)
11 skin rash 58 Frequent (79-30%)
12 gingival bleeding 58 Occasional (29-5%)
13 petechiae 58 Occasional (29-5%)
14 bruising susceptibility 58 Occasional (29-5%)
15 headache 58 Very frequent (99-80%)
16 lethargy 58 Occasional (29-5%)
17 cerebral hemorrhage 58 Occasional (29-5%)
18 pruritus 58 Frequent (79-30%)
19 diarrhea 58 Occasional (29-5%)
20 leukopenia 58 Occasional (29-5%)
21 hypoproteinemia 58 Occasional (29-5%)
22 cardiorespiratory arrest 58 Occasional (29-5%)

Clinical features from OMIM®:

614371 (Updated 05-Apr-2021)

UMLS symptoms related to Dengue Virus:


fever; pruritus

GenomeRNAi Phenotypes related to Dengue Virus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.55 RPSA
2 Decreased viability GR00221-A-2 9.55 NRBP1
3 Decreased viability GR00221-A-3 9.55 NRBP1
4 Decreased viability GR00240-S-1 9.55 PAF1 RPSA
5 Decreased viability GR00249-S 9.55 IFITM1 LGALS9 RPSA
6 Decreased viability GR00381-A-1 9.55 IFITM1 RPSA
7 Decreased viability GR00386-A-1 9.55 STAT2
8 Decreased viability GR00402-S-2 9.55 AUP1 LGALS9 NRBP1 PAF1 RPSA SHFL

Drugs & Therapeutics for Dengue Virus

Drugs for Dengue Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
2
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
3 Neurotransmitter Agents Phase 4
4 Histamine Antagonists Phase 4
5
Histamine Phosphate Phase 4 51-74-1 65513
6 Dermatologic Agents Phase 4
7 Histamine H1 Antagonists Phase 4
8 Anti-Allergic Agents Phase 4
9
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 6474909
10 Anti-Infective Agents Phase 2, Phase 3
11 Antiparasitic Agents Phase 2, Phase 3
12 Antibodies Phase 3
13 Immunoglobulins Phase 3
14 Immunologic Factors Phase 3
15 Vaccines Phase 3
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 2
17 Pharmaceutical Solutions Phase 2
18 Plasma-lyte 148 Phase 2
19
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
20
Aluminum sulfate Approved Phase 1 10043-01-3
21
Varespladib methyl Investigational Phase 1 172733-08-3
22 Gastrointestinal Agents Phase 1
23 Adjuvants, Immunologic Phase 1
24 Antacids Phase 1
25 Anti-Ulcer Agents Phase 1
26
Zanamivir Approved, Investigational Early Phase 1 139110-80-8 60855
27 Immunoglobulins, Intravenous
28 gamma-Globulins
29 Rho(D) Immune Globulin
30 Antiviral Agents Early Phase 1

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
3 Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
4 An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(Ies) for Dengue Completed NCT03771963 Phase 3
5 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico Completed NCT02979535 Phase 3
6 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
7 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia Completed NCT02993757 Phase 3
8 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Demonstrate Lot-to-Lot Consistency of 3 Lots of a Tetravalent Dengue Vaccine Candidate in Healthy Adults in Non-Endemic Country(Ies) for Dengue Completed NCT03423173 Phase 3
9 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
10 Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage Recruiting NCT04076254 Phase 3 Albumins;Fluid
11 A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue Active, not recruiting NCT03999996 Phase 3
12 A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscular Recombinant 9-Valent Human Papillomavirus (9vHPV) Vaccine in Subjects Aged ≥9 to <15 Years in an Endemic Country for Dengue Not yet recruiting NCT04313244 Phase 3
13 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines Terminated NCT02992418 Phase 3
14 A Phase I/II, Open, Five-year, Clinical Follow-up Study of Thai Children Who Participated in Dengue-003 ("A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children") With Evaluation of a Booster Dose Given One Year After Primary DEN Vaccination Series Completed NCT01843621 Phase 1, Phase 2
15 A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
16 A Phase 1/2, Randomized, Observer-blind Study of Varying Injection Schedules of a Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) With AS03B Adjuvant and Placebo in Healthy Adults in the US Completed NCT02421367 Phase 1, Phase 2
17 Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
18 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
19 Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children Completed NCT00468858 Phase 2
20 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
21 A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America Completed NCT02302066 Phase 2
22 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore Completed NCT02824198 Phase 2
23 An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults Completed NCT03746015 Phase 2
24 Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
25 Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3- Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines Completed NCT02628444 Phase 2
26 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America Completed NCT02623725 Phase 2
27 A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore Completed NCT02425098 Phase 2
28 A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
29 Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore Completed NCT00880893 Phase 2
30 Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years Completed NCT00740155 Phase 2
31 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
32 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam Completed NCT00875524 Phase 2
33 Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand Completed NCT00842530 Phase 2
34 Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixture TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh Completed NCT02678455 Phase 2
35 Phase II, Randomized, Double-blind, Clinical Tial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan Recruiting NCT04133987 Phase 2
36 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil Active, not recruiting NCT02741128 Phase 2
37 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of IC14 in Adult Patients With Dengue Fever Withdrawn NCT03875560 Phase 2 Placebo
38 A Phase Ib/IIa Single Centre, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Dose Ranging Trial in Adult Participants With Uncomplicated Dengue Fever in Singapore Withdrawn NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
39 Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Immunogenicity of DENVax Vaccine in Healthy Adults Completed NCT01224639 Phase 1
40 A Phase 1 Trial of the Walter Reed Army Institute of Research (WRAIR) Dengue Virus Serotype-1 Purified Inactivated Vaccine (DENV-1 PIV) in Flavivirus Antibody Naïve Adults Completed NCT01502735 Phase 1
41 A Phase 1, Randomized, Open-label, Single-center, Study of TDENV-PIV and LAV Dengue Vaccine Platforms as Part of a Heterologous Prime-boost Strategy in Healthy Adults in a Nonendemic Region Completed NCT02239614 Phase 1
42 A Phase 1 Study To Evaluate The Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue (Serotype 1, 2, 3, and 4) Plasmid DNA Vaccine (TVDV) Formulated With and Without Vaxfectin® Completed NCT01502358 Phase 1
43 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Dengue Virus Polymerase Inhibitor (Balapiravir) in Male Patients With Confirmed Dengue Virus Infection Completed NCT01096576 Phase 1 balapiravir [RO4588161];placebo
44 Evaluation of the Clinical and Immune Response Generated by Heterologous Attenuated Dengue Virus Infection Completed NCT02392325 Phase 1
45 A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of WRAIR Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in Puerto Rico Completed NCT01702857 Phase 1
46 A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of Walter Reed Army Institute of Research (WRAIR) Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in a Non-Endemic Region Completed NCT01666652 Phase 1
47 A Double-Blind Randomized, Placebo-Controlled, Phase I Dose Escalation Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Completed NCT01110551 Phase 1 Placebo (SC);Placebo (ID)
48 A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With Attenuated DENV-2, rDEN2∆30-7169 Completed NCT02317900 Phase 1
49 A Phase 1 Evaluation of the Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV003 to Protect Against Infection With Attenuated DENV-2, rDEN2∆30-7169 Completed NCT02021968 Phase 1
50 Phase 1 Study of the Safety and Immunogenicity of rDEN2/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 2 Completed NCT00094705 Phase 1

Search NIH Clinical Center for Dengue Virus

Genetic Tests for Dengue Virus

Genetic tests related to Dengue Virus:

# Genetic test Affiliating Genes
1 Dengue Virus, Susceptibility to 29 CD209

Anatomical Context for Dengue Virus

MalaCards organs/tissues related to Dengue Virus:

40
Endothelial, T Cells, Monocytes, Brain, Skin, B Cells, Kidney

Publications for Dengue Virus

Articles related to Dengue Virus:

(show top 50) (show all 9708)
# Title Authors PMID Year
1
A variant in the CD209 promoter is associated with severity of dengue disease. 57 6 61
15838506 2005
2
IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity. 57 61
28126818 2017
3
Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. 61 57
26138103 2015
4
Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development. 57 61
25939314 2015
5
A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies. 61 57
21107723 2011
6
Dengue: a continuing global threat. 61 57
21079655 2010
7
Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. 61 57
20855599 2010
8
Discovery of insect and human dengue virus host factors. 57 61
19396146 2009
9
CLEC5A is critical for dengue-virus-induced lethal disease. 61 57
18496526 2008
10
Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. 57 61
12783086 2003
11
Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. 57
22001756 2011
12
The pathogenesis of dengue. 57
21781999 2011
13
Dengue hemorrhagic fever is associated with polymorphisms in JAK1. 57
20588308 2010
14
Promoter variation in the DC-SIGN-encoding gene CD209 is associated with tuberculosis. 6
16379498 2006
15
Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. 6
15564514 2004
16
Viral evolution sustains a dengue outbreak of enhanced severity. 61
33686914 2021
17
Retrospective meta-transcriptomic identification of severe dengue in a traveller returning from Africa to Sweden, 1990. 61
33553563 2021
18
A comparative genomics-based study of positive strand RNA viruses emphasizing on SARS-CoV-2 utilizing dinucleotide signature, codon usage and codon context analyses. 61
33615042 2021
19
Animals as potential reservoirs for dengue transmission: A systematic review. 61
33598525 2021
20
Generation and characterization of luciferase-secreting, single-round infectious DENV-2 reporter for functional antibody assays. 61
33662412 2021
21
On the role of surrounding regions in the fusion peptide in dengue virus infection. 61
33667752 2021
22
Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study. 61
33212067 2021
23
A regional suitable conditions index to forecast the impact of climate change on dengue vectorial capacity. 61
33561446 2021
24
In silico studies of the inhibition mechanism of dengue with papain. 61
32249700 2021
25
Circulation of dengue serotype 1 viruses during the 2019 outbreak in Dar es Salaam, Tanzania. 61
33797341 2021
26
Malaysian outcome of acute necrotising encephalopathy of childhood. 61
33358123 2021
27
Novel insights into the function of an N-terminal region of DENV2 NS4B for the optimal helicase activity of NS3. 61
33485995 2021
28
Molecular evolution of dengue virus types 1 and 4 in Korean travelers. 61
33575893 2021
29
Boosting can explain patterns of fluctuations of ratios of inapparent to symptomatic dengue virus infections. 61
33811138 2021
30
Current Knowledge and Ecological and Human Impact Variables Involved in the Distribution of the Dengue Virus by Bats in the Americas. 61
33439764 2021
31
Systemic dengue infection associated with a new dengue virus type 2 introduction in Brazil - a case report. 61
33794785 2021
32
Valosin-containing protein ATPase activity regulates the morphogenesis of Zika virus replication organelles and virus-induced cell death. 61
33432690 2021
33
Structural and biochemical insights into flavivirus proteins. 61
33607183 2021
34
Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies. 61
33694220 2021
35
Presentation of fatal stroke due to SARS-CoV-2 and dengue virus coinfection. 61
32881018 2021
36
Successful treatment of positive-sense RNA virus coinfection with autoimmune hepatitis using double filtration plasmapheresis. 61
33766959 2021
37
Traditional Chinese Medicine (TCM) in the treatment of viral infections: Efficacies and mechanisms. 61
33811957 2021
38
Surveillance of the major pathogenic arboviruses of public health concern in Gabon, Central Africa: increased risk of West Nile virus and dengue virus infections. 61
33731022 2021
39
The Insect-Specific Parramatta River Virus Is Vertically Transmitted by Aedes vigilax Mosquitoes and Suppresses Replication of Pathogenic Flaviviruses In Vitro. 61
33325801 2021
40
Learning from the past: development of safe and effective COVID-19 vaccines. 61
33067570 2021
41
Changes in the dynamics of dengue incidence in South and Central America are possibly due to cross-population immunity after Zika virus epidemics. 61
33190402 2021
42
First Report of Aedes albopictus (Diptera: Culicidae) in District Mirpur, Azad Jammu and Kashmir, Pakistan. 61
32990723 2021
43
Simultaneous circulation of zakat, dengue, and chikungunya viruses and their vertical co-transmission among Aedes aegypti. 61
33406443 2021
44
The optimal age of vaccination against dengue in Brazil based on serotype-specific forces of infection derived from serological data. 61
32671383 2021
45
Evaluation of kinase inhibitors as potential therapeutics for flavivirus infections. 61
33683474 2021
46
Risk of chronic arthralgia and impact of pain on daily activities in a cohort of patients with chikungunya virus infection from Brazil. 61
33684559 2021
47
Comparison of Anti-Dengue and Anti-Zika IgG on a Plasmonic Gold Platform with Neutralization Testing. 61
33782214 2021
48
Three-Year Clinical Follow-Up of Children Intrauterine Exposed to Zika Virus. 61
33810110 2021
49
Severe dengue outbreak associated with DENV-3 in the city of Manado, North Sulawesi, Indonesia. 61
33774189 2021
50
A graphene-based dengue immunosensor using plant-derived envelope glycoprotein domain III (EDIII) as the novel probe antigen. 61
33523052 2021

Variations for Dengue Virus

ClinVar genetic disease variations for Dengue Virus:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CD209 CD209, -336A-G SNV protective 5408 GRCh37:
GRCh38:

Expression for Dengue Virus

Search GEO for disease gene expression data for Dengue Virus.

Pathways for Dengue Virus

GO Terms for Dengue Virus

Cellular components related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.83 RSAD2 RPSA PAF1 OAS3 NRBP1 MRC1
2 transcriptionally active chromatin GO:0035327 9.16 PAF1 CTR9
3 Cdc73/Paf1 complex GO:0016593 8.62 PAF1 CTR9

Biological processes related to Dengue Virus according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.11 RSAD2 OAS3 LGALS9 IFITM3 IFITM2 IFITM1
2 viral process GO:0016032 10.1 STAT2 RSAD2 RPSA MRC1 IFIH1 HAVCR1
3 innate immune response GO:0045087 10 SHFL RSAD2 OAS3 IFITM3 IFITM2 IFITM1
4 viral entry into host cell GO:0046718 9.88 RPSA MRC1 HAVCR1 CLEC5A CD209
5 negative regulation of viral genome replication GO:0045071 9.8 SHFL RSAD2 OAS3 IFITM3 IFITM2 IFITM1
6 positive regulation of interleukin-6 production GO:0032755 9.78 LGALS9 IFIH1 DDX58
7 positive regulation of tumor necrosis factor production GO:0032760 9.77 LGALS9 IFIH1 DDX58
8 response to interferon-gamma GO:0034341 9.76 SHFL IFITM3 IFITM2 IFITM1
9 response to interferon-beta GO:0035456 9.73 SHFL IFITM3 IFITM2 IFITM1
10 type I interferon signaling pathway GO:0060337 9.7 STAT2 RSAD2 OAS3 IFITM3 IFITM2 IFITM1
11 negative regulation of viral entry into host cell GO:0046597 9.69 IFITM3 IFITM2 IFITM1
12 response to interferon-alpha GO:0035455 9.67 IFITM3 IFITM2 IFITM1
13 positive regulation of interferon-alpha production GO:0032727 9.62 IFIH1 DDX58
14 negative regulation of myeloid cell differentiation GO:0045638 9.62 PAF1 CTR9
15 cellular response to exogenous dsRNA GO:0071360 9.61 IFIH1 DDX58
16 histone monoubiquitination GO:0010390 9.59 PAF1 CTR9
17 histone modification GO:0016570 9.58 PAF1 CTR9
18 histone H2B ubiquitination GO:0033523 9.58 PAF1 CTR9
19 positive regulation of response to cytokine stimulus GO:0060760 9.57 IFIH1 DDX58
20 detection of virus GO:0009597 9.56 IFIH1 DDX58
21 response to virus GO:0009615 9.56 RSAD2 OAS3 IFITM3 IFITM2 IFITM1 IFIH1
22 endodermal cell fate commitment GO:0001711 9.55 PAF1 CTR9
23 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.54 IFIH1 DDX58
24 regulation of type III interferon production GO:0034344 9.52 IFIH1 DDX58
25 defense response to virus GO:0051607 9.32 STAT2 SHFL RSAD2 OAS3 IFITM3 IFITM2

Molecular functions related to Dengue Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded RNA binding GO:0003725 9.33 OAS3 IFIH1 DDX58
2 mannose binding GO:0005537 9.26 MRC1 CD209
3 carbohydrate binding GO:0030246 9.26 MRC1 LGALS9 CLEC5A CD209
4 virus receptor activity GO:0001618 9.02 RPSA MRC1 HAVCR1 CLEC5A CD209

Sources for Dengue Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....